Corina® Approved by Singapore HSA, Achieving Market Authorization in 10 Overseas Countries

Corina® Approved by Singapore HSA, Achieving Market Authorization in 10 Overseas Countries
Singapore | February 2024
On February 6, 2024, Corina® Intrauterine Drug-Eluting Stent, independently designed and developed by Yipurun (Shanghai) Biotechnology Co., Ltd., received its market approval from the Singapore Health Sciences Authority (HSA).
To date, Corina® has been approved in 10 overseas countries, including seven Asia-Pacific markets—Singapore, Thailand, the Philippines, Indonesia, Vietnam, Malaysia, and New Zealand—and three Latin American countries: Colombia, Peru, and Bolivia.
As the world’s first drug-eluting anti-adhesion intrauterine device independently developed and manufactured in China, these approvals represent a significant milestone in Corina®’s global regulatory and commercialization strategy. The company will continue to accelerate international market expansion to address unmet clinical needs worldwide.